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Lars Bjerrum15, Isabel Amo8, Nieves Barragán16 and Carl Llor17*Abstract
Background: Despite their marginal benefit, about 60% of acute lower respiratory tract infections (ALRTIs) are
currently treated with antibiotics in Catalonia. This study aims to evaluate the effectiveness and efficiency of a
continuous disease-focused intervention (C-reactive protein [CRP]) and an illness-focused intervention
(enhancement of communication skills to optimise doctor-patient consultations) on antibiotic prescribing in
patients with ALRTIs in Catalan primary care centres.
Methods/design: A cluster randomised, factorial, controlled trial aimed at including 20 primary care centres
(N = 2940 patients) with patients older than 18 years of age presenting for a first consultation with an ALRTI will be
included in the study. Primary care centres will be identified on the basis of socioeconomic data and antibiotic
consumption. Centres will be randomly assigned according to hierarchical clustering to any of four trial arms: usual
care, CRP testing, enhanced communication skills backed up with patient leaflets, or combined interventions. A
cost-effectiveness and cost-utility analysis will be performed from the societal and national healthcare system
perspectives, and the time horizon of the analysis will be 1 year. Two qualitative studies (pre- and post-clinical trial)
aimed to identify the expectations and concerns of patients with ALRTIs and the barriers and facilitators of each
intervention arm will be run. Family doctors and nurses assigned to the interventions will participate in a 2-h
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training workshop before the inception of the trial and will receive a monthly intervention-tailored training module
during the year of the trial period. Primary outcomes will be antibiotic use within the first 6 weeks, duration of
moderate to severe cough, and the quality-adjusted life-years. Secondary outcomes will be duration of illness and
severity of cough measured using a symptom diary, healthcare re-consultations, hospital admissions, and
complications. Healthcare costs will be considered and expressed in 2021 euros (year foreseen to finalise the study)
of the current year of the analysis. Univariate and multivariate sensitivity analyses will be carried out.
Discussion: The ISAAC-CAT project will contribute to evaluate the effectiveness and efficiency of different strategies
for more appropriate antibiotic prescribing that are currently out of the scope of the actual clinical guidelines.
Trial registration: ClinicalTrials.gov, NCT03931577.
Keywords: Cost-effectiveness, Cost-utility, Effectiveness, Anti-bacterial agents, Prescribing, Acute cough, Respiratory
tract infections, Antimicrobial stewardship, Qualitative research, Incremental cost-utility ratio, Primary healthcareBackground
Overuse of antibiotics has contributed to the develop-
ment of antimicrobial resistance, which represents a
major threat to human health worldwide [1]. In addition
to driving resistance, non-indicated use of antibiotics in-
curs costs, increases re-consultation for subsequent epi-
sodes, medicalizes self-limiting illness, and unnecessarily
exposes individuals to the risk of side effects. Most anti-
biotics are prescribed in primary care, most commonly
for acute lower respiratory tract infections (ALRTI),
which account for one-fourth of all the infectious dis-
eases treated by general practitioners (GPs). According
to a study carried out in Catalonia, about 60% of ALRTIs
are currently treated with antibiotics [2]. The latest
Cochrane review also suggests that only a slight benefit
is achieved from the prescription of antibiotics [3]. Be-
cause no new classes of antibiotics have been developed
in the last two decades, rationalisation of antibiotic use
in the treatment of ALRTIs in primary care is a key tar-
get for influencing the antibiotic-prescribing behaviour
of clinicians [1]. This supports the case for strategies
that promote a more prudent use of antibiotics for these
infections. This is even more important in Catalonia, be-
cause this is one of the European Union countries with
the highest rates of antibiotic prescribing, which has
even slightly increased in the last years [4, 5]. This find-
ing is also supported by the results of the latest Euroba-
rometer on antibiotic use carried out in 2016, in which
47% of the Spanish respondents admitted having taken
an antibiotic in the previous year [6].
Antibiotic use can be improved by using educational in-
terventions such as dissemination of printed and audio-
visual educational materials, group education, personal or
group feedback, individual outreach visits, reminders at the
time of prescribing, and computer-assisted decision-making
systems, among others, but these interventions generally re-
sult in little change in prescription practices, although the
effect is greater with multi-faceted approaches [7, 8]. In a
recent Cochrane review of systematic reviews aimed atassessing the effects of interventions targeting clinician anti-
biotic prescribing for ALRTIs in primary care, the reviewers
found that the most powerful tools for reducing unneces-
sary antibiotic prescribing are C-reactive protein (CRP)
rapid testing, shared decision making, and procalcitonin-
guided management without compromising outcomes of
patient satisfaction and re-consultation, although the meas-
urement of these outcomes was limited in the trials [9].
The antibiotic prescribing behaviour of GPs for acute
cough in adults is influenced by their perceptions of
patient expectations, but sometimes their perceptions do
not match patient views [10]. Patients report lower levels
of satisfaction with their consultation if they have an
expectation for antibiotics that is not met, and being
able to effectively elicit patient views towards shared
decisions is therefore an important skill for clinicians
managing acute cough. Interactive workshops for health-
care professionals and education of patients are likely to
lower the rate of antibiotic prescribing [10]. A Dutch
study found that the training of physicians in advanced
communication skills by seminar role-playing and peer
feedback on consultation transcripts reduced antibiotic
prescribing rates by 20% [11]. In a Welsh study a 4%
reduction in global antibiotic use was found after web-
based training in advanced communication skills [12].
CRP testing has been shown to safely reduce antibiotic
prescribing in primary care [13]. In a Dutch study, training
of physicians in CRP testing lowered the rate of antibiotic
prescribing by 20%, but the greatest reduction was ob-
served among GPs assigned to CRP testing and enhanced
communication skills training [11]. In a multinational
study conducted in Europe, which assessed the effects of
internet-based training on antibiotic prescribing for acute
respiratory tract infections, both CRP and clinician training
in communication skills were effective in reducing anti-
biotic prescribing, but the greatest reduction was also seen
when both the CRP testing and communication skills
training interventions were combined [14]. The effect of
the communication skills training was greater in the Dutch
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intervention was more intense and continuous. In the latter
study, however, the intervention was limited to a single
online training lasting approximately 1 h before the trial
started. In addition, patients were followed for only 4
weeks, whereas approximately 25% of patients still have
cough after this period, and patients still re-attended their
GPs because full recovery was not accomplished.
Recent evidence showed that ambulatory antibiotic pre-
scription is associated with a hidden cost of antibiotic re-
sistance that substantially increases the cost of an antibiotic
prescription [15]. This finding raises concerns regarding the
magnitude of misalignment between individual and societal
antibiotic costs. There is a lack of evidence evaluating the
efficiency of different multi-faceted approaches in order to
decrease the inappropriate prescribing of antibiotics in
Mediterranean countries. Although CRP point-of-care tests
are widely used in a number of European countries for the
management of ALRTIs, they are not yet routinely used in
Catalonia. In addition, these overprescribing actions could
lead to inefficiencies of the health system.
Methods/design
Objectives
This study aims to evaluate the effectiveness and effi-
ciency of a continuous (workshop and monthly web-
based training) disease-focused intervention (CRP
testing) and a continuous (on-site and monthly online
training) illness-focused intervention (enhancement
of communication skills to optimise doctor-patient
consultations and share decision making with the aid
of patient-centred leaflets) on antibiotic prescribing
in patients with ALRTIs in Catalan primary care cen-
tres. An economic evaluation of four strategies for
reducing antibiotic prescribing will be performed. Par-
ticularly, a cost-effectiveness and cost-utility analysis will
be conducted. These interventions will be compared with
the current antibiotic prescribing strategy used in the pri-
mary care centres. The analysis will be conducted from
the societal and the national healthcare system perspec-
tives. Two qualitative studies (pre- and post-clinical trial)
will be also conducted to inform the development and
evaluation of the clinical trial.
Study design
A cluster randomised, factorial, controlled trial performed
over a period of 18months including two autumn-winter
seasons will be carried out. A randomised cluster design
will be used to keep contamination (influence on partici-
pants’ behaviour when another participant or physician
alters his/her behaviour) within primary care centres to a
minimum, because three GPs and nurses per centre are
expected to participate and because a centre-based meet-
ing is part of the intervention. Patients who fulfil theinclusion criteria will be given written and verbal informa-
tion about the study and will be asked to provide written
informed consent.
The inclusion criteria will be age older than 18 years
and first consultation for acute cough (new cough or
worsening of a previous cough) of up to 3 weeks’ duration
as the predominant symptom, which the clinician believes
to be an infectious ALRTI, as defined in other studies [3].
The exclusion criteria will be a working diagnosis of a
non-infective disorder, such as heart failure, pulmonary
embolus, oesophageal reflux, or allergy; use of antibiotics
in the previous 2 weeks; immunological deficiencies; and/
or inability to provide informed consent or unable to fol-
low the study procedures. Pneumonia and acute exacerba-
tions of chronic obstructive pulmonary disease will not be
deemed as exclusion criteria, because they are included in
the ALRTI definition. The Standard Protocol Items: Rec-
ommendation for Interventional Trials (SPIRIT) Checklist
is provided as Additional file 1.
Sample size calculation
To calculate the sample size, we will use a type I error of
5% and a power of 80%, and we will assume that antibiotic
prescribing will decrease by at least 15%, from 60% to 45%,
in any one of the three intervention groups. We will also
assume a drop-out rate of 12% and an intra-cluster correl-
ation coefficient for antibiotic prescribing within practices
of up to 0.07, based on two recent studies [14, 16]. We esti-
mate that a sample of 788 (197 × 4) patients will be needed.
Allowance for an inflation factor of 3.73 due to clustering
and rounding of numbers for the four subgroups give an
overall sample size of 2940 [17]. As a consequence, at least
147 patients will be recruited per centre.
Setting and timing
General practices throughout Catalonia in the localities of
the study centres (with different socioeconomic levels) will
be approached, and at least three pairs of clinicians (GPs
and nurses) in eligible centres will be invited to partici-
pate. Eligible centres will be stratified depending on the
socioeconomic level and baseline antibiotic consumption,
and only those that had not previously used any interven-
tion to reduce antibiotic prescribing rates will be selected.
They are expected to include 150 patients (75 patients in
each autumn-winter season) in the trial.
Trial interventions
The centres will be randomly assigned to four trial arms:
usual care, training in the use of a point-of-care CRP test,
training in enhanced communication skills, or combined
training in CRP testing and enhanced communication
skills (Fig. 1). Masking of GPs or patients to the interven-
tion itself is not possible. Randomisation of primary care
Fig. 1 Flowchart of the randomised clinical trial. ALRTI acute lower respiratory tract infection
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dom numbers.
An on-the-spot 2-h training workshop will take place
in the different areas before the inception of the trial.
This training will be followed by monthly internet-based
short training capsules tailored to either of the two
interventions measured (clinical cases, medical literature,
reminders) that GPs allocated to this intervention will
have to attend and answer. GPs assigned to both inter-
ventions will receive the two training programmes. The
usual care group will assess and manage patients accord-
ing to the practice’s normal procedures.
The CRP group will receive internet training on how to
target testing (e.g., in cases of clinical uncertainty, such as in
patients with abnormal auscultation, dyspnoea, and impair-
ment of vital signs) and how to negotiate with the patient
about management decisions. The tests will be carried out
with Afinion 2 CRP devices (Abbott Diagnostics, Lake For-
est, IL, USA). Clinicians (GPs and nurses) will practise using
the device during a run-in period of 2 weeks before data col-
lection starts. GPs will be informed about the updated rec-
ommendations on how to interpret the CRP values and the
evidence-based management (no antibiotics, delayed anti-
biotic prescribing or immediate antibiotic prescribing).
Training in enhanced communication skills will focus on the
gathering of information on patients’ concerns and
expectations, exchange of information on symptoms, natural
disease course and treatments, agreement of a management
plan, red flags, and providing guidance about when to re-
consult and summing up. GPs will also be provided with an
interactive booklet to use during consultations that includes
information on symptoms, use of antibiotics and antibiotic
resistance, self-help measures, and when to re-consult, and
the booklet will be given to the patient. This training will be
supported by video demonstrations of consultation tech-
niques. GPs will also be informed about the updated recom-
mendations on management of ALRTIs.
Outcome measures
During the index consultation GPs will document the
duration of the illness, the severity of cough and other
symptoms (rated 0, not problematic; to 6, severely prob-
lematic), and the severity of the infections. After ran-
domisation a more detailed case report form (CRF) will
be used in the follow-up consultations and will include
the same details as the index form plus medical history,
current medications, smoking status, findings of struc-
tured examination, whether CRP is tested, and whether
the booklet is used. The primary outcome measures will
be antibiotic consumption within the first 6 weeks, as
documented in the CRFs and double-checked by the
Pharmacy Unit of the Catalan Institute of Health, which
can track if the antibiotic has been dispensed at any of
the Catalan pharmacies; the duration of moderate tosevere cough (i.e., those rating their cough as 3 or more
by means of a Likert scale); and the quality-adjusted life-
years (QALYs), which will be collected by means of the
EQ-5D-5L questionnaire within the first 6 weeks
(Table 1).
Secondary outcome measures are listed in Table 2.
The duration of symptoms rated moderate to severe will
also be recorded. Because this study will follow patients
for 6 weeks, we will be able to better define the duration
of acute cough due to ALRTI. Symptoms will be rated
daily as 0 (no problem) to 6 (as bad as it could be) until
they resolve, and the information will be reported by pa-
tients in self-completed diaries, similar to what was done
in a recent clinical trial on delayed antibiotic prescribing
carried out in Catalonia [18]. For patients who do not
return diaries, a short form asking about the details of
the duration and severity of symptoms and whether anti-
biotics have been taken or whether the booklet has been
used will be completed by telephone call to the patient.
The data collection process and the rest of the study
procedures will be supervised. A clinical research associ-
ate will perform periodic visits to the sites and provide
online supervision of the data. A data monitoring com-
mittee has been deemed not necessary because of the
study characteristics, as well as external audits. Never-
theless, the coordinating team will hold periodic meet-
ings, and study procedures will be reviewed.
Resource use and costs
Micro-costing techniques will be used to estimate the
healthcare costs for patients with acute cough in the dif-
ferent interventions. The costs will be presented in 2021
euros (year foreseen to finalize the study). Primary data of
the ISAAC-CAT clinical trial will be used whenever pos-
sible. The costs will include the costs of treatment to con-
trol the acute cough and management of these patients.
The cost of treatment will depend on the state of health of
the patient but may include the costs of the different ther-
apies prescribed, including those recommended to be pur-
chased at the pharmacies. The costs of management will
include the cost of primary care and secondary care visits
within the first 6 weeks as well as any diagnostic tests per-
formed and the number of days of patient absenteeism.
The cost of the interventions will cover the continuous
training, including the workshop and the monthly delivery
of training microcapsules, the cost of the booklets, the
cost of the CRP machine, and the reagents used.
Cost-effectiveness and cost-utility analyses
The cost-effectiveness analysis will be conducted com-
paring costs and effectiveness/utility, measured in nat-
ural units and QALYs, respectively, of the different
alternatives to usual practice. In most cases the data will
be obtained from the ISAAC-CAT clinical study. The
Table 1 Schedule of enrolment, interventions and assessments for the clinical trial
Time point Study period
November 4, 2019–April 30, 2021
Day 1 Week 2 Week 6
Enrolment
Medical history and physical examination X
Explanation of the study and informed consent X
Initial CRF X
Giving out of the symptom diary, up to week 2 X
Interventions
CRP rapid test if needed (only among those patients visited
by professionals assigned to the CRP intervention groups)*
X
Use of an interactive booklet (only among those patients
visited by professionals assigned to the enhanced
communication skill intervention groups)*
X
Assessments
Assessment of the clinical outcome X X
Collection and review of the symptom diary X
EQ-5D-5L questionnaire X X X
Antibiotic consumption X X X
Use of drugs other than antibiotics X X X
Tests ordered by clinicians X X X
Patient satisfaction with care X X
Patient perception of the usefulness of the information received X X
Patient future consulting intentions X X
Absenteeism X X X
Evaluation of adverse events X X
Number of re-consultations to primary and secondary care and
number of complications regarding the ALRTI
X
Abbreviations: ALRTI acute lower respiratory tract infection, CRF case report form, CRP C-reactive protein, GP general practitioner
Randomisation will take place 2 weeks before initiating the clinical trial (October 21, 2019). Workshop for GPs and nurses assigned to any of the three intervention
arms at the end of October 2019
*Monthly internet-based short training capsules for GPs and nurses assigned to any of the intervention groups
Ruiz et al. Trials          (2019) 20:740 Page 6 of 9comparison will be performed using the incremental
cost-effectiveness ratio and the incremental cost-
utility ratio, defined as the ratio of the difference in
costs and the difference in effectiveness or utility.
The results will be expressed in terms of euros per
unit of effectiveness.
Statistical analysis
Analyses will be carried out by intention to treat and will
use multilevel logistic regression modelling with differ-
ent distributions of errors according to the objective
analysed for a factorial study controlled for the baseline
antibiotic prescribing rate and with allowance for clus-
tering by GP and health centre. The effects of various
potential confounders related to clinical severity will be
explored because of the potential for selection bias in an
open trial. If interactions between interventions are not
significant, the results will be presented as the maineffects of each intervention (e.g., factorial groups with
estimates controlling mutually for each intervention).
The analysis will be performed using Stata 15 econometric
software (StataCorp, College Station, TX, USA).
To study uncertainty, univariate and multivariate de-
terministic sensitivity analyses of the relevant parameters
considered will be undertaken.
Qualitative studies
There will be two qualitative studies, one pre- and one
post-clinical trial. A phenomenologist framework will be
applied in both studies. This is a relevant approach be-
cause the qualitative studies aim to explore the experi-
ences of ALRTIs and healthcare in primary care settings
among participants in their own words and through
their own interpretations of their realities [19]. Sampling
will be theoretical and purposive and will include a
number of pathways to ensure maximum inclusivity.
Table 2 Secondary objectives and outcome measures
Objectives Outcome measures Time point(s) of evaluation of this
outcome measure
Number of re-consultations to primary and secondary
care and number of complications regarding the
ALRTI
Re-consultation for new or worsening symptoms, new
signs, or hospital admission, assessed by review of
medical notes (practice staff, the local study team, or
both using a standard form to report these data), and
number of complications regarding the ALRTI
First 6 weeks post-randomisation
Duration of moderate to severe symptoms Number of days until the last day any of the
symptoms is rated 3 or more. Symptoms will be rated
daily as 0 (no problem) to 6 (as bad as it could be)
until they resolve, and the information will be reported
by patients in self-completed diaries.
First 6 weeks post-randomisation
Antibiotic prescription at the baseline visit,
differentiating immediate and delayed antibiotic
prescribing, and antibiotic dispensing at the
pharmacies
Reported in the CRF. The number of patients treated
with immediate and delayed antibiotic prescribing will
be evaluated. Dispensing of the antibiotics at the
pharmacies.
Baseline visit. The dispensing of
antibiotics will be tracked in the
first 6 weeks post-randomisation.
Drugs other than antibiotics Reported by patients in self-completed diaries First 6 weeks post-randomisation
Tests ordered by clinicians Reported in the CRF Baseline visit
Patient satisfaction with care Reported in the symptom diaries First 6 weeks post-randomisation
Patient perception of the usefulness of the
information received
Collected in the symptom diaries First 6 weeks post-randomisation
Patient future consulting intentions Collected in the symptom diaries First 6 weeks post-randomisation
Serious adverse events Assessed by review of medical notes (practice staff, the
local study team, or both using a standard form to
report these data)
First 6 weeks post-randomisation
Number of days of sick leave (absenteeism) Collected in the CRFs First 6 weeks post-randomisation
ALRTI acute lower respiratory tract infection, CRF case report form
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Semi-structured individual interviews (n = 30) and a group
discussion (n = 8–12 participants) will be conducted with
patients diagnosed with an ALRTI in the pre-clinical trial
study. This qualitative pre-clinical trial study will aim to
explore past experiences with ALRTIs, expectations and
preferences of treatment, patients’ understanding of the
symptoms of ALRTIs, the relationship with healthcare
professionals, and perceived communication skills of
healthcare professionals. Data collection will take place in
the primary care clinics where participants are recruited.
The interviews will take 45–60min, and the group discus-
sion will last about 90min. They will all take place in the
primary care centres. The semi-structured interviews and
group discussion will be audio-recorded and transcribed
systematically and verbatim. All data collection will be
conducted by the same technical expert from the research
team. The topic guide for the group discussion will be de-
veloped on the basis of findings from the interviews. All
interviews will be conducted in the two official languages
(Spanish and Catalan).
Post-clinical trial study
The aim of this study will be to investigate the satisfaction,
pros, and cons of GPs, nurses, and patients assigned to the
different intervention trial arms. For this study, 35 healthcare
professionals (GPs and nurses) and 30 patients will berecruited. Recruitment will be carried out as for the pre-
clinical trial study. The methods of data collection will be dif-
ferent for healthcare professionals and patients. Healthcare
professionals will be asked to take part in a World Café [20],
and patients will be recruited for individual semi-structured
interviews as for the pre-intervention study. Through World
Café we will generate GP and nurse collective knowledge
about what are the preferences, needs, experiences, strengths
and limitations in reducing inappropriate antibiotic prescrib-
ing for adults with ALRTIs.
Data analyses
A thematic content analysis will be performed on the
basis of information obtained in the interviews and
World Café. The data will be analysed in the following
manner. After successive readings of the transcribed in-
terviews, the researchers will attain some pre-analytical
insight into the data. Next, four researchers will conduct
the following analytical steps:
1. Identification of the relevant subjects and texts
2. Fragmentation of the text into units of meaning
3. Text codification with emerging codes from the data
4. Creation of categories by grouping the codes based
on the criterion of similarity
5. Analysis of each category
6. Elaboration of new text with the results
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research team members until a consensus is reached (tri-
angulation). The analysis will be performed using NVivo
software (QSR International, Doncaster, Australia).Discussion
ALRTIs are very prevalent diseases and one of the most fre-
quent causes of medical visits in primary care [21]. Despite
most of these infections’ being self-limiting conditions,
most patients feel ill, and many do not perform their usual
activities. Patients often return to their physician or seek
other medical help because the symptoms may persist,
mainly cough, which may be very bothersome for some
[22]. Furthermore, patients with bronchitis miss an average
of 2–3 days of work per episode [23]. In addition, many pa-
tients are prescribed antibiotics unnecessarily.
Rapid testing, such as CRP testing, has been widely
promoted for improving the care of with ALRTIs [1].
Most evaluations of diagnostic devices consider analytic
performance without evaluating impact on patient out-
comes or costs. However, new tests should not be intro-
duced into routine clinical care if they do not improve
outcomes that matter to patients individually or to soci-
ety, including consideration of impact on recovery and
quality of life, antibiotic prescribing, and antibiotic re-
sistance [24]. Efficiency is also a relevant criterion for
health decision making. The enhancement of clinician
communication skills with the provision and discussion
of leaflets targeted to the population has also demon-
strated a powerful tool to reduce inappropriate antibiotic
prescribing. However, the continuous training in these
interventions has never been investigated.Trial status
Recruitment opened on 18 November 2019 and is expected
to continue to 30 April 2021.Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3727-3.
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Interventional Trials (SPIRIT) 2013 checklist: recommended items to
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